Algeta ASA is an oncology company based in Oslo, Norway, dedicated to developing targeted therapies for cancer patients using its innovative alpha-pharmaceutical platform. The company's lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing the development of thorium-227 conjugates, which involve linking the alpha-emitter to tumor-targeting molecules, currently in the preclinical phase. Algeta has established a collaboration with Bayer Pharma AG for the global development and commercialization of radium-223. Founded in 1997, the company originally operated under the name Anticancer Therapeutic Inventions AS before rebranding as Algeta ASA in 2003.